Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Issue 9 (September 2022)

• Record Type: Journal Article
• Authors: Coyne, Daniel W.; Singh, Ajay K.; Lopes, Renato D.; Bailey, Christine K.; DiMino, Tara L.; Huang, Chun; Connaire, Jeffrey; Rastogi, Anjay; Kim, Sung-Gyun; Orias, Marcelo; Shah, Sapna; Patel, Vickas; Cobitz, Alexander R.; Wanner, Christoph
• Is Part Of: Clinical journal of the American Society of Nephrology. Volume 17:Issue 9(2022)
• Page Start: 1325
• Page End: 1336
• Publication Date: 2022-09
• Subjects: hemodialysis -- hemoglobin -- erythropoietin -- anemia -- clinical trial -- blood pressure -- epoetin -- randomized controlled trials -- hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) -- chronic kidney disease
• DOI: 10.2215/CJN.00550122
• Languages: English
• ISSNs: 1555-9041

Abstract

Visual Abstract: Abstract : Background and objectives: Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being investigated for the treatment of anemia of CKD. In this noninferiority trial, we compared daprodustat administered three times weekly with epoetin alfa (epoetin) in patients on prevalent hemodialysis switching from a prior erythropoiesis-stimulating agent (ESA). Design, setting, participants, & measurements: Patients on hemodialysis with a baseline hemoglobin of 8–11.5 g/dl receiving an ESA were randomized 2:1 to daprodustat three times weekly ( n =270) or conventional epoetin ( n =137) for 52 weeks. Dosing algorithms aimed to maintain hemoglobin between 10 and 11 g/dl. The primary end point was mean change in hemoglobin from baseline to the average during the evaluation period (weeks 28–52). The principal secondary end point was average monthly intravenous iron dose. Other secondary end points included BP and hemoglobin variability. Results: Daprodustat three times weekly was noninferior to epoetin for mean change in hemoglobin (model-adjusted mean treatment difference [daprodustat-epoetin], −0.05; 95% confidence interval, −0.21 to 0.10). During the evaluation period, mean (SD) hemoglobin values were 10.45 (0.55) and 10.51 (0.85) g/dl for daprodustat and epoetin groups, respectively. Responders (defined as mean hemoglobin during the evaluation period in the analysis range of 10 to 11.5 g/dl) were 80% in the daprodustat group versus 64% in the epoetin group. Proportionately fewer participants in the daprodustat group versus the epoetin group had hemoglobin values either below 10 g/dl or above 11.5 g/dl during the evaluation period. Mean monthly intravenous iron use was not significantly lower with daprodustat versus epoetin. The effect on BP was similar between groups. The percentage of treatment-emergent adverse events was similar between daprodustat (75%) and epoetin (79%). Conclusions: Daprodustat was noninferior to epoetin in hemoglobin response and was generally well tolerated. Clinical Trial registry name and registration number: Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat–Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033